TY - JOUR
T1 - Variability of disease spectrum in children with liver phosphorylase kinase deficiency caused by mutations in the PHKG2 gene
AU - Bali, Deeksha S.
AU - Goldstein, Jennifer L.
AU - Fredrickson, Keri
AU - Rehder, Catherine
AU - Boney, Anne
AU - Austin, Stephanie
AU - Weinstein, David A.
AU - Lutz, Richard
AU - Boneh, Avihu
AU - Kishnani, Priya S.
N1 - Funding Information:
We would like to thank the patients and families who participated in this research study. We are grateful to the Association for Glycogen Storage Diseases, US and the YT and Alice Chen Pediatric Genetics and Genomics Center at Duke for funding this research. Support for this project was also provided by the National Institutes of Health (NIH)/NCATS Clinical and Translational Science Award to the University of Florida UL1 TR000064, Matthew's GSD Type IX Fund , and the Sturtz GSD Research Fund managed by the University of Florida Foundation.
PY - 2014/3
Y1 - 2014/3
N2 - Liver phosphorylase b kinase (PhK) deficiency (glycogen storage disease type IX), one of the most common causes of glycogen storage disease, is caused by mutations in the PHKA2, PHKB, and PHKG2 genes. Presenting symptoms include hepatomegaly, ketotic hypoglycemia, and growth delay. Clinical severity varies widely. Autosomal recessive mutations in the PHKG2 gene, which cause about 10-15% of cases, have been associated with severe symptoms including increased risk of liver cirrhosis in childhood. We have summarized the molecular, biochemical, and clinical findings in five patients, age 5-16. years, diagnosed with liver PhK deficiency caused by PHKG2 gene mutations. We have identified five novel and two previously reported mutations in the PHKG2 gene in these five patients. Clinical severity was variable among these patients. Histopathological studies were performed for four of the patients on liver biopsy samples, all of which showed signs of fibrosis but not cirrhosis. One of the patients (aged 9. years) developed a liver adenoma which later resolved. All patients are currently doing well. Their clinical symptoms have improved with age and treatment. These cases add to the current knowledge of clinical variability in patients with PHKG2 mutations. Long term studies, involving follow-up of these patients into adulthood, are needed.
AB - Liver phosphorylase b kinase (PhK) deficiency (glycogen storage disease type IX), one of the most common causes of glycogen storage disease, is caused by mutations in the PHKA2, PHKB, and PHKG2 genes. Presenting symptoms include hepatomegaly, ketotic hypoglycemia, and growth delay. Clinical severity varies widely. Autosomal recessive mutations in the PHKG2 gene, which cause about 10-15% of cases, have been associated with severe symptoms including increased risk of liver cirrhosis in childhood. We have summarized the molecular, biochemical, and clinical findings in five patients, age 5-16. years, diagnosed with liver PhK deficiency caused by PHKG2 gene mutations. We have identified five novel and two previously reported mutations in the PHKG2 gene in these five patients. Clinical severity was variable among these patients. Histopathological studies were performed for four of the patients on liver biopsy samples, all of which showed signs of fibrosis but not cirrhosis. One of the patients (aged 9. years) developed a liver adenoma which later resolved. All patients are currently doing well. Their clinical symptoms have improved with age and treatment. These cases add to the current knowledge of clinical variability in patients with PHKG2 mutations. Long term studies, involving follow-up of these patients into adulthood, are needed.
KW - Glycogen storage disease type IX
KW - Hypoglycemia
KW - Liver adenoma
KW - PHKG2 gene
KW - Phosphorylase b kinase deficiency
UR - http://www.scopus.com/inward/record.url?scp=84894449637&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84894449637&partnerID=8YFLogxK
U2 - 10.1016/j.ymgme.2013.12.008
DO - 10.1016/j.ymgme.2013.12.008
M3 - Article
C2 - 24389071
AN - SCOPUS:84894449637
SN - 1096-7192
VL - 111
SP - 309
EP - 313
JO - Biochemical Medicine and Metabolic Biology
JF - Biochemical Medicine and Metabolic Biology
IS - 3
ER -